Tempus AI and Stemline Therapeutics partner to advance AI-driven ESR1 mutation testing in metastatic breast cancer
Tempus AI, Inc. (NASDAQ: TEM) and Stemline Therapeutics, Inc., a wholly owned subsidiary of the Menarini Group, have announced a collaboration to integrate Tempus Next, ... Read More
Roche secures FDA approval for HER2-ultralow metastatic breast cancer diagnostic
Roche has received FDA approval for an expanded use of its PATHWAY HER2 (4B5) test, marking a significant breakthrough in breast cancer diagnostics. This development ... Read More
Datroway approved in US: A new era in metastatic breast cancer treatment
In a landmark decision, the US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan), a first-in-class TROP2-directed antibody-drug conjugate (ADC) developed by AstraZeneca ... Read More
Breakthrough in breast cancer treatment? BriaCell Therapeutics shares soar 150%!
BriaCell Therapeutics Corp., a clinical-stage biotechnology company, saw its shares surge by more than 150% to $1.55 following the release of positive overall survival data ... Read More
Gilead’s Trodelvy gains EC approval as new hope for metastatic breast cancer patients
In a significant advancement for cancer treatment, the European Commission (EC) has approved Gilead Sciences' Trodelvy (sacituzumab govitecan) for the treatment of adult patients suffering ... Read More
Menarini’s ORSERDU gets CHMP positive opinion in advanced breast cancer
The Menarini Group and its subsidiary, Stemline Therapeutics Inc., have received a favorable opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for ... Read More
AstraZeneca, Daiichi Sankyo’s Enhertu approved for breast cancer in China
The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for use as a monotherapy in ... Read More
Gilead gets Trodelvy FDA approval for pre-treated HR+/HER2- metastatic breast cancer
Gilead Sciences has secured the approval of the US Food and Drug Administration (FDA) for Trodelvy (sacituzumab govitecan-hziy) for pre-treated HR+/HER2- metastatic breast cancer. The ... Read More
FDA approves Guardant360 CDx assay as companion diagnostic for Menarini’s ORSERDU for metastatic breast cancer
Guardant Health, an oncology company, has secured the approval of the US Food and Drug Administration (FDA) for the company’s Guardant360 CDx liquid biopsy assay ... Read More
Enhertu EU approval : Daiichi Sankyo, AstraZeneca get approval for HER2 low metastatic breast cancer
Daiichi Sankyo and AstraZeneca have received the approval of the European Union (EU) for their jointly developed Enhertu (trastuzumab deruxtecan) for the treatment of a ... Read More